IP Library › Granted Patent US 11,059,909

Granted Patent B2

US 11,059,909 · App. 17/091,897 · Granted Jul 13, 2021

Engineered IgA antibodies and methods of use

Inventors: Jeanette Henrica Wilhelmina Leusen (Utrecht, NL); Johannes Gerardus Maria Evers (Utrecht, NL); Geert Jan Van Tetering (Utrecht, NL)

Assignee: UMC UTRECHT HOLDING B.V.

C07K16/4283 C07K16/283 C07K16/2887 A61K2039/505 C07K2317/41 C07K2317/51 C07K2317/522 C07K2317/524 C07K2317/526 C07K2317/565 C07K2317/732 C07K2317/94

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,059,909
App. No.: 17/091,897
Granted: Jul 13, 2021
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.

Claims (127)

1. An engineered antibody or a functional fragment thereof that comprises:

a) an antibody antigen binding domain; and

b) a constant domain, wherein the constant domain comprises an immunoglobulin A (IgA) heavy chain constant region,

wherein the IgA heavy chain constant region comprises an IgA CH2 region, an IgA CH3 region, and an IgA CH1 region, and

wherein the IgA heavy chain constant region comprises:

i) a N45.2G amino acid substitution, and

ii) a deletion of C-terminal amino acid residues P131-Y148,

relative to a WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

2. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region further comprises:

i) a C86S amino acid substitution,

ii) a P124R amino acid substitution,

iii) a N114T amino acid substitution,

iv) a I115L amino acid substitution,

v) a T116S amino acid substitution, or

vi) a combination thereof,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

3. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region comprises;

i) the N45.2G amino acid substitution,

ii) the deletion of C-terminal amino acid residues P131-Y148,

iii) a N114T amino acid substitution,

iv) a 1115L amino acid substitution,

v) a T116S amino acid substitution,

vi) a C86S amino acid substitution, and

vii) a P124R amino acid substitution,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

4. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region further comprises:

i) an amino acid substitution selected from the group consisting of N15.2G, N15.2Q, and N15.2T,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

5. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region comprises:

i) the N45.2G amino acid substitution,

ii) the deletion of C-terminal amino acid residues P131-Y148,

iii) a N114T amino acid substitution,

iv) a I115L amino acid substitution,

v) a T116S amino acid substitution,

vi) an amino acid substitution selected from the group consisting of N15.2G, N15.2Q, and N15.2T,

vii) a L15.3I amino acid substitution, and

viii) a T16S amino acid substitution,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to the IMGT scheme.

6. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region further comprises:

i) an amino acid substitution selected from the group consisting of N15.2G, N15.2Q, and N15.2T,

ii) a L15.3I amino acid substitution,

iii) a T16S amino acid substitution,

iv) a C86S amino acid substitution,

v) a P124R amino acid substitution, or

vi) a combination thereof,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

7. The engineered antibody or the functional fragment thereof of claim 6 , wherein the IgA heavy chain constant region further comprises:

i) the amino acid substitution selected from the group consisting of N15.2G, N15.2Q, and N15.2T,

ii) the L15.3I amino acid substitution,

iii) the T16S amino acid substitution,

iv) the C86S amino acid substitution, and

v) the P124R amino acid substitution,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

8. The engineered antibody or the functional fragment thereof of claim 1 , wherein the IgA heavy chain constant region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-21.

9. The engineered antibody or the functional fragment thereof of claim 1 , wherein the antibody antigen binding domain comprises a heavy chain variable region that comprises a complementarity determining region heavy chain 1 (HC-CDR1), a HC-CDR2, and a HC-CDR3, wherein

(a) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 33,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 41, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 49;

(b) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 34,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 42, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 50;

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 43, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 51;

(d) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 36,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 44, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 52;

(e) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 37,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 45, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 53;

(f) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 38,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 46, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 54;

(g) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 39,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 47,

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 55; or

(h) the HC-CDR1 comprises amino acid sequence SEQ ID NO: 40,

the HC-CDR2 comprises amino acid sequence SEQ ID NO: 48, and

the HC-CDR3 comprises amino acid sequence SEQ ID NO: 56.

10. The engineered antibody or the functional fragment thereof of claim 1 , wherein the antibody antigen binding domain comprises a light chain variable region that comprises a complementarity determining region light chain 1 (LC-CDR1), a LC-CDR2, and a LC-CDR3, wherein

(a) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 57,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 65, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 73;

(b) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 58,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 66, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 74;

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 67, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 75;

(d) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 60,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 68, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 76;

(e) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 61,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 69, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 77;

(f) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 62,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 70, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 78;

(g) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 63,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 71, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 79; or

(h) the LC-CDR1 comprises amino acid sequence SEQ ID NO: 64,

the LC-CDR2 comprises amino acid sequence SEQ ID NO: 72, and

the LC-CDR3 comprises amino acid sequence SEQ ID NO: 80.

11. The engineered antibody or the functional fragment thereof of claim 9 , wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NOs: 4, 7, 81-86.

12. The engineered antibody or the functional fragment thereof of claim 10 , wherein the light chain variable region comprises a sequence selected from the group consisting of SEQ ID NOs: 5, 8, 95-100.

13. A pharmaceutical composition comprising the engineered antibody or the functional fragment thereof of claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.

14. An engineered antibody or a functional fragment thereof that comprises:

a) an antibody antigen binding domain; and

b) a constant domain, wherein the constant domain comprises an immunoglobulin A (IgA) heavy chain constant region,

wherein the IgA heavy chain constant region comprises an IgA CH2 region, and an IgA CH3 region,

wherein the IgA heavy chain constant region comprises a

i) an amino acid substitution selected from the group consisting of N15.2G, and N15.2T,

relative to a WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

15. The engineered antibody or the functional fragment thereof of claim 14 , wherein the IgA heavy chain constant region further comprises an IgA CH1 region; and

i) a N114T amino acid substitution,

ii) a N45.2G amino acid substitution, or

iii) a N114T amino acid substitution, and a N45.2G amino acid substitution,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

16. The engineered antibody or the functional fragment thereof of claim 14 , wherein the IgA heavy chain constant region further comprises:

i) a C86S amino acid substitution,

ii) a P124R amino acid substitution,

iii) a deletion of C147,

iv) a deletion of Y148,

v) a deletion of C-terminal amino acid residues P131-Y148, or

vi) a combination thereof,

relative to the WT IgA heavy chain constant region comprising amino acid sequence SEQ ID NO: 1, numbering according to IMGT scheme.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2021

From: UMC UTRECHT HOLDING B.V.

To: TIGA TX, INC.

Reel/Frame 057798/0458 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2021

From: LEUSEN, JEANETTE HENRICA WILHELMINA; EVERS, JOHANNES GERARDUS MARIA; VAN TETERING, GEERT JAN

To: UMC UTRECHT HOLDING B.V.

Reel/Frame 054937/0134 →

Continuity (3)

Continuation PCTNL2020050217 · Mar 27, 2020

Provisional Application 62824864 · Mar 27, 2019

Related Publication 20210122834A1 · Apr 29, 2021

Cited By (2)

US 12,258,420 US 12,630,650